Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.45 CHF 0.95% Market Closed
Market Cap: 141.9m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

Wall Street
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 14.08 CHF with a low forecast of 12.93 CHF and a high forecast of 15.75 CHF.

Lowest
Price Target
12.93 CHF
74% Upside
Average
Price Target
14.08 CHF
89% Upside
Highest
Price Target
15.75 CHF
111% Upside
Newron Pharmaceuticals SpA Competitors:
Price Targets
ANCR
Animalcare Group PLC
32% Upside
002262
Jiangsu Nhwa Pharmaceutical Co Ltd
26% Upside
INVA
Innoviva Inc
7% Downside
069620
Daewoong Pharma
38% Upside
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
42% Downside
JUBLPHARMA
Jubilant Pharmova Ltd
7% Upside

Revenue
Forecast

Revenue Estimate
Newron Pharmaceuticals SpA

For the last 8 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 19%. The projected CAGR for the next 3 years is 32%.

19%
Past Growth
32%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NWRN's stock price target?
Price Target
14.08 CHF

According to Wall Street analysts, the average 1-year price target for NWRN is 14.08 CHF with a low forecast of 12.93 CHF and a high forecast of 15.75 CHF.

What is Newron Pharmaceuticals SpA's Revenue forecast?
Projected CAGR
32%

For the last 8 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 19%. The projected CAGR for the next 3 years is 32%.

Back to Top